A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT06949761 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: QLC1101+QL1203
DRUG: QLC1101+QL2107
DRUG: QLC1101+QL1706
DRUG: QLC1101+docetaxel

Sponsor

Qilu Pharmaceutical Co., Ltd.